Please assess the completion status of the following clinical trial:

Trial Title: A Study of LY2127399 in Participants With Systemic Lupus Erythematosus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Clinical diagnosis of SLE as defined by American College of Rheumatology (ACR) criteria~* Have positive antinuclear antibodies (ANA)~* Agree not to become pregnant throughout the course of the trial~* Have a screening SELENA-SLEDAI score ≥6. (The participant must be actively exhibiting all the symptoms scored on the screening SELENA-SLEDAI on the day of screening.)~Exclusion Criteria:~* Have active severe Lupus kidney disease~* Have active Central Nervous System or peripheral neurologic disease~* Have received intravenous immunoglobulin (IVIg) within 180 days of randomization~* Have active or recent infection within 30 days of screening~* Have had a serious infection within 90 days of randomization~* Have evidence or test positive for Hepatitis B~* Have Hepatitis C~* Are human immunodeficiency virus (HIV) positive~* Have evidence of active or latent tuberculosis (TB)~* Presence of significant laboratory abnormalities at screening~* Have had a malignancy in the past 5 years, except for cervical carcinoma in-situ or basal cell or squamous epithelial skin cell that were completely resected with no reoccurrence in the 3 yrs prior to randomization~* Have received greater than 40 mgs of prednisone or equivalent in the past 30 days~* Have changed your dose of antimalarial drug in the past 30 days~* Have changed your dose of immunosuppressive drug in the past 90 days~* Have previously received rituximab

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- LY2127399 every 2 weeks (Type: EXPERIMENTAL): None
- LY2127399 every 4 weeks (Type: EXPERIMENTAL): During the Treatment Period, for blinding purposes, participants will alternate injections of LY2127399 and injections of placebo every 2 weeks.
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).